Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Amber Biolife

2014 FOUNDED
M&A STATUS
Corporate LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Developer of biologic therapeutic products. The company p is focused on the development and commercialization of a novel processed human platelet lysate technology (Aurarix) as a stem cell growth supplement (UltraGro Advanced) and as a biologic eye drop for dry eye syndrome (Elate Ocular).

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Acquirer
Zheng Yang Biomedical Technology Company
Primary Office
  • Seattle, WA
  • United States

Amber Biolife Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Amber Biolife‘s full profile, request access.

Request full access to PitchBook